# MacroGenics (MGNX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MGNX
## Company Profile
- Ticker: MGNX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 4.02 USD
- Market cap: 257430648.14999998 USD
- Last updated: 2026-08-12
## Business Overview
### Antibody Engineering Company
MacroGenics develops antibody-based cancer therapies using internal platforms for monoclonal antibodies, bispecific molecules, and antibody-drug conjugates.
### ADC Portfolio
MGC026 targets B7-H3 and is in Phase 1 dose expansion, while MGC028 targets ADAM9 and is in Phase 1 dose escalation across advanced solid tumors.
### Focused R&D Model
Following divestiture of its manufacturing operation, MacroGenics is concentrating resources on drug discovery, clinical development, partnerships, and royalty interests such as ZYNYZ.
## Why The Stock Is Moving

The latest monitored company update is “MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initiation of the Phase 1 dose-escalation study of MGC030 in the third quarter of 2026.
- MGC026 and lorigerlimab clinical data presentations at ESMO 2026.
- Preliminary clinical results from the MGC028 dose-escalation study in late 2026.

## Recent News
- 2026-08-13 20:05 EST — [MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position](https://biopharmsignal.com/news/MGNX/macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating--1ac14c3d) — Source: MacroGenics
- 2026-08-11 20:05 EST — [MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program](https://biopharmsignal.com/news/MGNX/macrogenics-announces-achievement-of-10-million-milestone-following-gilead-s-exe-0e7f032c) — Source: MacroGenics
- 2026-07-23 20:01 EST — [MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026](https://biopharmsignal.com/news/MGNX/macrogenics-provides-clinical-update-on-ongoing-phase-1-study-for-mgc026-66fcf182) — Source: MacroGenics
- 2026-07-02 13:25 EST — [MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals](https://biopharmsignal.com/news/MGNX/macrogenics-completes-sale-of-gmp-manufacturing-operations-to-bora-pharmaceutica-b2889ad8) — Source: MacroGenics
- 2026-06-22 20:43 EST — [MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval](https://biopharmsignal.com/news/MGNX/macrogenics-to-receive-milestone-payment-from-sanofi-for-recent-tzield-approval-201de8b5) — Source: MacroGenics